



## Renal Cell Carcinoma – Risk Factors, genetics, and therapeutic research development

**Shavy Nagpal**

*The Research Institute of St. Joe's Hamilton (Uro – Oncology), Department of Surgery, St. Joseph's Healthcare Hamilton, Canada*

### **Abstract:**

Research focus: Investigating Olaparib, a selective inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP2 and PARP-3) in renal cell carcinoma. Approved by Health Canada for BRCA mutation positive ovarian cancer, and germline BRCA – mutated HER2 – negative metastatic breast cancer. Research focus on DNA repair gene mutations and studying its therapeutic potential.

Renal Cell Carcinoma is among 10th most common cancer in both genders with a mortality of 4,970 out of 14,830 among women. 1 in 82 women are diagnosed with renal cell carcinoma which accounts for about (1.02%). It can present either alone or concomitant with other solid tumors such as, breast and ovarian cancer. My research area is investigating the role of BRCA mutations/ DNA repair gene mutations (BAP 1 – BRCA associated protein 1 in renal cancer) that share an overlapping occurrence. This is used to develop novel therapeutic pathways that can possibly improve overall progression free survival,



and quality of life for our patients. We will talk about modifiable and non – modifiable risk factors, and how the latter can be pro – actively improved through novel research/ clinical trials. The presentation will also walk you through a real case management of concomitant breast (first diagnosis), and renal cell carcinoma (concomitant diagnosis). Thank you for your time, and please feel free to have your questions ready for me.

**Webinar on Women Health Science and Care, 7 September, 2020, Tokyo, Japan**

**Citation:** Shavy Nagpal, The Research Institute of St. Joe's Hamilton (Uro – Oncology), Department of Surgery, St. Joseph's Healthcare Hamilton, Canada. Webinar on Women Health Science and Care, 7 September, 2020, Tokyo, Japan